June 17, 2019
NRG Oncology Broadcast archives are accessible from our website at any time. Please bookmark  this link  for your convenience.

NRG Oncology Trial Reaffirms Carboplatin and Paclitaxel Chemotherapy Alone Should Remain Standard Treatment for Endometrial Cancer

Read more

 
 

Only 9 days left to have your registration fee waived!

We hope you can join us for the NRG Oncology Semiannual Meeting, July 18-20, 2019, at the Philadelphia Marriott Downtown in Philadelphia, PA. Pre-Registration for this meeting is complimentary for all NRG members who pre-register by the deadline of June 25, 2019. We kindly ask that everyone please pre-register for this meeting before the deadline. Onsite registration will incur a $100 fee.

 

Registration and meeting information is available on the NRG Oncology website.

 

Meeting Highlights

  • Patient Reported Outcomes: Upping the game for PRO methods and design in clinical trials

    NRG Oncology will be holding a workshop at the NRG Semiannual Meeting related to improving statistical methods to meet study goals, analyzing longitudinal PRO data as well as a panel discussion with NCORP PIs. This session will be held on Thursday, July 18, 2019 from 1-5pm and will be open to all attendees. The agenda can be found here.

  • Summer SymposiumThursday, July 18 -  8am-3pm Read more
  • Scientific Session: Friday, July 19 -  8-10am
  • Health Disparities Workshop Special Session: S exual and Gender Minority Related Activities at the NIH - Friday, July 19 – 10-11:30am Read more
  • Social Media Workshop:  Friday, July 19 - 11:30am-12:30pm Read more

SAVE THE DATE: Information Session for NRG-BN006

NRG Oncology will be holding an information session for NRG-BN006:  A Phase II/III Randomized, Open-Label Study of Toca 511, A Retroviral Replicating Vector, Combined with Toca FC with Temozolomide and Radiation Followed by Adjuvant Temozolomide and Toca FC Compared to Temozolomide and Radiation Followed by Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma on Friday, July 19, 2019 from 10:30-11am ET. The information session will be held at the NRG Oncology Semiannual Meeting in Philadelphia and is open to all attendees. More information on the information session agenda and room location will be released soon. Please contact Erin Moye at moyee@nrgoncology.org for any questions at this time.

 

SAVE THE DATE: Kick-Off Session for NRG-GU007

NRG Oncology will be holding a kick-off session for NRG-GU007: Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I) on Friday, July 19, 2019 from 11am-12pm ET. The information session will be held at the NRG Oncology Semiannual Meeting in Philadelphia and is open to all attendees. More information on the kick-off session agenda and room location will be released soon. Please contact Erin Moye at moyee@nrgoncology.org for any questions.

 

SAVE THE DATE: Kick-Off Session for NRG-LU003

NRG Oncology will be holding a kick-off session at the NRG Oncology Semiannual Meeting for NRG-LU003 “A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol.” The session will be held on Saturday, July 20, 2019 from 10:30-11:30am ET and will be open to all attendees. More information on the session and agenda are posted here. Please contact Erica Field at fielde@nrgoncology.org for any questions.

 

SAVE THE DATE: Kick-Off Session for NRG-LU005

NRG Oncology will be holding an kick-off session for NRG-LU005: Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab on Friday, July 19, 2019 from 3-4pm ET. The kick-off session will be held at the NRG Oncology Semiannual Meeting in Philadelphia and is open to all attendees. More information on the kick-off session agenda and room location will be released soon.  Please contact Erin Moye at moyee@nrgoncology.org for any questions.

Social Media Workshop 1-on-1's at #NRG19

Are you ready to get started on Twitter?  Let our social media experts show you how simple it is to set up a new account or make your existing account more engaging. At #NRG19, we have scheduled two Social Media 1-on-1 Workshops where our Twitter experts will be on hand to show you the how-to's of Twitter. If you are interested in learning more about tweeting, retweeting, hashtags, following, and more, stop by during one of the following sessions and bring your smartphone &/or laptop. No previous social media experience required! Friday, July 19, 12:30-1pm and Saturday, July 20, 10-11am. Meet the experts here


OTHER PROTOCOL NOTICES

1. GYNECOLOGIC

NRG-GY009: Block Submission Reminder memo (posted on  CTSU)

Form TR for Biospecimens Shipped to NRG Biospecimen Bank-Columbus Read more


Biospecimen Bank-Columbus & SDMC Undergoing Refurbishment Read more


2. LUNG

NRG-RTOG 1308:  The June 2019 newsletter has been posted to the CTSU website > Supplemental Documents tab.

3. NCORP

NRG-CC004: Last chance to register for the NRG-CC004 webinar occurring this Wednesday, June 19th Read more

4. VTOC TRAINING

The VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on RTOG 0924, RTOG 0920, NRG-HN001, NRG-HN002, NRG-CC003 and NRG-CC004. The VisionTree staff will be at the round table session during the NRG semiannual meeting on July 18. Please stop by to learn more about VTOC.

 

DRUG SAFETY UPDATES AND INVESTIGATOR'S BROCHURE NOTICES

Safety updates and Investigator's Brochure notices have been issued for the following studies:

 

DRUG NAME

PROTOCOL

WEBSITE FOR SAFETY REPORTS

INVESTIGATOR'S BROCHURE (IB)

Atezolimumab

NRG-BR004
NRG-GI004/
SWOG S1610

NRG-GY009
NRG-GY017
NRG-LU005

CTSU


CTSU
CTSU
NRG
CTSU

 

Ensartinib

NRG-LU003

CTSU

X*

Olaparib

NSABP B-55

CTSU

X**

 

*The current version of the Investigator Brochure Documents for Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI)-sponsored trials are available for access via the Cancer Therapy Evaluation Program (CTEP) Online Agent Order Processing (OAOP) website ( https://ctepcore.nci.nih.gov/OAOP/ ). Log-in using your Identity and Access Management (IAM) username and password credentials and provide the requested information to access the document.

Every site principal investigator is responsible for reviewing this document. The Investigator Brochure is for use by the site principal investigator and any study personnel under his/her supervision who need to know the contents for the conduct of a clinical trial, including Institutional Review Board(s) or Independent Ethics Committee(s).

 

**I nformation about  the updated Olaparib IB in the context of NSABP B-55 was posted on June 3, 2019; however, it was not indicated in the June 3 broadcast. NRG Oncology members can download the June 3 IB announcement and the updated Olaparib IB from the B-55 page on the NRG Oncology website.

 

CRA and CTN Membership Program 

Are you a new CRA or CTN within NRG Oncology?  Would you like a mentor to help guide you through your new role as a CRA or CTN?  Are you an institution in need of more guidance after an audit? The Mentorship Working Group can provide you a mentor! You can apply for a mentor by going to the NRG Oncology website at www.nrgoncology.org and click on the CRA/CTN tab, then Mentorship link. You will find the Mentor Form and instructions on the Mentorship Program web page. Hope to hear from you soon!

 

NRG Oncology Trial Reaffirms Carboplatin and Paclitaxel Chemotherapy Alone Should Remain Standard Treatment for Endometrial Cancer

The New England Journal of Medicine recently published the primary endpoint of the NRG Oncology clinical trial NRG-GOG 0258, which showed that carboplatin and paclitaxel chemotherapy preceded by radiotherapy with concurrent cisplatin, or combined modality therapy, did not significantly increase recurrence-free survival for women with stage 3-4A endometrial cancer when compared to chemotherapy with carboplatin and paclitaxel alone. These results were also presented in abstract form at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting. Read more

 

Dr. Abraham Reflects on #ASCO19

Jame Abraham, MD, a Professor of Medicine and Director of the Breast Oncology Program at Taussig Cancer Institute at Cleveland Clinic, recently published an article titled, "What Special Area of Knowledge Do You Bring to the Oncology World?" on Op-Med Voices from the Doximity Network, about his recent experience attending the 2019 ASCO Annual Meeting, including hearing the Gianni Bonadonna Breast Cancer Award lecture given by Norman Wolmark, MD, one of the NRG Oncology group chairs and NSABP Foundation chairman. Click here to read. 

Last Chance to Register! NRG-CC004 Webinar

NRG Oncology will be holding a webinar for NRG-CC004: Phase II Double Blind Dose Finding Trial of Bupropion versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer. The webinar will occur on Wednesday, June 19 from 4:00-5:00 PM ET.

Register at: https://attendee.gotowebinar.com/register/4196058926907886595

Please contact Angie LaPenta at lapentaa@nrgoncology.org with any questions.


PUBLICATIONS REMINDERS

 

Please note the following upcoming meeting and abstract submission deadline dates

Upcoming Meetings

American Association of Physicists in Medicine (AAPM); Jul 14-18, 2019; San Antonio, TX

 

Upcoming Abstract Submission Deadlines

European Society for Medical Oncology (ESMO); Sep 27-Oct 1, 2019; Barcelona, Spain; LBA Aug 21, 2019 9:00 pm CEST

San Antonio Breast Cancer Symposium (SABCS); Dec 10-14, 2019; San Antonio, TX; due to publications committee Jun 24, 2019; meeting submission deadline Jul 8, 2019

NRG Oncology is proud to be an active participant of #CancerMoonShot.
This message was sent from NRG-Broadcasts@NRGOncology.org to NRG-Broadcasts@NRGOncology.org
Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Update Profile/Email Address | Forward Email | Report Abuse